Company intelligence / Profile preview

one.bio

Davis, California, United Statesone.bio ↗

Ownership: Private
Development stage: Other

Overview

one.bio develops proprietary plant-derived fiber ingredients ("WholeFibers™") that are integrated into food products to restore beneficial dietary fibers lost in modern diets. Their technology produces novel oligosaccharides that modulate the microbiome and immune system. The company is commercial-stage with no traditional pharmaceutical clinical pipeline[1][2].

Therapeutic areas: Metabolic Disorders
Modalities: OligosaccharidesDietary fibers (WholeFibers™)
Industry: Non-Drug Biotech

Partnerships

Not specifically listed; serves both food industry and biopharma sectors[2]

Beyond the preview

Go deeper on one.bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on one.bio.

Explore the full profile